Because of these limitations and the promising results of EPO on neurodevelopment-related outcomes in neonates with hypoxic-ischemic encephalopathy (HIE) (33, 34) and very low birthweight infants (35), a larger RCT would be required to definitively address the neuroprotective effects of EPO in this CHD population. Here, EPO is linked to perinatal asphyxia.